Skip to Content

SpringWorks Therapeutics Inc Ordinary Shares SWTX

Morningstar Rating
$44.84 +0.07 (0.16%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SWTX is trading at a 487% premium.
Price
$44.43
Fair Value
$73.97
Uncertainty
Extreme
1-Star Price
$938.12
5-Star Price
$48.39
Economic Moat
Ywwvb
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SWTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$44.77
Day Range
$43.8044.95
52-Week Range
$18.0053.92
Bid/Ask
$30.00 / $44.89
Market Cap
$3.32 Bil
Volume/Avg
630,433 / 970,265

Key Statistics

Price/Earnings (Normalized)
Price/Sales
111.85
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
305

Comparables

Valuation

Metric
SWTX
VRDN
CELC
Price/Earnings (Normalized)
Price/Book Value
5.852.443.86
Price/Sales
111.852,512.88
Price/Cash Flow
Price/Earnings
SWTX
VRDN
CELC

Financial Strength

Metric
SWTX
VRDN
CELC
Quick Ratio
6.2117.9310.64
Current Ratio
6.4118.2611.23
Interest Coverage
−137.76−13.89
Quick Ratio
SWTX
VRDN
CELC

Profitability

Metric
SWTX
VRDN
CELC
Return on Assets (Normalized)
−40.43%−42.76%−40.23%
Return on Equity (Normalized)
−46.62%−82.42%−56.35%
Return on Invested Capital (Normalized)
−50.77%−50.70%−44.81%
Return on Assets
SWTX
VRDN
CELC
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRZghndhtrngPqz$586.1 Bil
VRTX
Vertex Pharmaceuticals IncRcqygjdmMmlzzx$113.7 Bil
REGN
Regeneron Pharmaceuticals IncPwqxcdnVcwsqzb$108.2 Bil
MRNA
Moderna IncDmqhhbccpSnypw$50.9 Bil
ARGX
argenx SE ADRZnsjkskxlWkpm$22.0 Bil
BNTX
BioNTech SE ADRFwryqcgfVbqbm$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncGblfzdghGfzypv$18.9 Bil
BMRN
Biomarin Pharmaceutical IncLzhstfkbsSvsffb$14.6 Bil
INCY
Incyte CorpVbnjfchrFmlvcs$12.8 Bil
RPRX
Royalty Pharma PLC Class AYpdzclnbnkTtcplf$12.3 Bil

Sponsor Center